Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans

British Journal of Anaesthesia

Volumn 117, Issue , 2016, Pages ii44-ii62

  Xia, Z ^a   Li, H ^a   Irwin, M G ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

anaesthetic conditioning; diabetes; ischaemia reperfusion injury; ischaemic conditioning

Indexed keywords

ANESTHETIC AGENT; INHALATION ANESTHETIC AGENT; NITRIC OXIDE; PROPOFOL; REACTIVE OXYGEN METABOLITE;

ANESTHESIA; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXPERIMENTAL ANIMAL; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; HEART INFARCTION PREVENTION; PHYSIOLOGY;

ANESTHETICS; ANIMALS; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE;

EID: 85015920789     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aew267     Document Type: Article

References (199)

1. Botto, F, Alonso-Coello, P, Chan, MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 120 (2014), 564–578.
2. Ferdinandy, P, Schulz, R, Baxter, GF, Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59 (2007), 418–458.
3. Johnson, AP, Parlow, JL, Whitehead, M, Xu, J, Rohland, S, Milne, B, Body mass index, outcomes, and mortality following cardiac surgery in Ontario, Canada. J Am Heart Assoc, 4, 2015 e002140.
4. Grundy, SM, Benjamin, IJ, Burke, GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999), 1134–1146.
5. Ishihara, M, Inoue, I, Kawagoe, T, et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38 (2001), 1007–1011.
6. Kristiansen, SB, Lofgren, B, Stottrup, NB, et al. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47 (2004), 1716–1721.
7. Przyklenk, K, Maynard, M, Greiner, DL, Whittaker, P, Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 14 (2011), 781–790.
8. Drenger, B, Ostrovsky, IA, Barak, M, Nechemia-Arbely, Y, Ziv, E, Axelrod, JH, Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology 114 (2011), 1364–1372.
9. Yellon, DM, Hausenloy, DJ, Myocardial reperfusion injury. N Engl J Med 357 (2007), 1121–1135.
10. Halestrap, AP, Richardson, AP, The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol 78C (2015), 129–141.
11. Di Lisa, F, Bernardi, P, Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 70 (2006), 191–199.
12. Di Lisa, F, Canton, M, Carpi, A, et al. Mitochondrial injury and protection in ischemic pre- and postconditioning. Antioxid Redox Signal 14 (2011), 881–891.
13. Castello, PR, David, PS, McClure, T, Crook, Z, Poyton, RO, Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab 3 (2006), 277–287.
14. Heusch, G, Boengler, K, Schulz, R, Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol 105 (2010), 151–154.
15. Walters, AM, Porter, GA Jr, Brookes, PS, Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 111 (2012), 1222–1236.
16. Halestrap, AP, Mitochondria and reperfusion injury of the heart–a holey death but not beyond salvation. J Bioenerg Biomembr 41 (2009), 113–121.
17. Griffiths, EJ, Halestrap, AP, Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307:Pt 1 (1995), 93–98.
18. Becker, LB, New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61 (2004), 461–470.
19. O'Rourke, B, Cortassa, S, Aon, MA, Mitochondrial ion channels: gatekeepers of life and death. Physiology (Bethesda) 20 (2005), 303–315.
20. Griffiths, EJ, Halestrap, AP, Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25 (1993), 1461–1469.
21. Skyschally, A, Schulz, R, Heusch, G, Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 24 (2010), 85–87.
22. Piot, C, Croisille, P, Staat, P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008), 473–481.
23. Tsujita, K, Shimomura, H, Kawano, H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 94 (2004), 481–484.
24. Schaller, S, Paradis, S, Ngoh, GA, et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther 333 (2010), 696–706.
25. Otani, H, Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 6 (2004), 449–469.
26. Takano, H, Zou, Y, Hasegawa, H, Akazawa, H, Nagai, T, Komuro, I, Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 5 (2003), 789–794.
27. Mao, X, Wang, T, Liu, Y, et al. N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1alpha/HO-1 signaling in diabetic rats. PloS One, 8, 2013, e68949.
28. Peterson, TE, Poppa, V, Ueba, H, Wu, A, Yan, C, Berk, BC, Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 85 (1999), 29–37.
29. Hausenloy, DJ, Yellon, DM, Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123 (2013), 92–100.
30. Xia, Z, Vanhoutte, PM, Nitric oxide and protection against cardiac ischemia. Curr Pharm Des 17 (2011), 1774–1782.
31. Xia, Z, Kuo, KH, Nagareddy, PR, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 73 (2007), 770–782.
32. Orhan, G, Yapici, N, Yuksel, M, et al. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart Vessels 21 (2006), 42–47.
33. Marchioli, R, Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol Res 40 (1999), 227–238.
34. Tribble, DL, AHA science advisory. antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation 99 (1999), 591–595.
35. Lonn, E, Bosch, J, Yusuf, S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (2005), 1338–1347.
36. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European myocardial infarction project–free radicals. Eur Heart J 21 (2000), 1537–1546.
37. Dabkowski, ER, Williamson, CL, Hollander, JM, Mitochondria-specific transgenic overexpression of phospholipid hydroperoxide glutathione peroxidase (GPx4) attenuates ischemia/reperfusion-associated cardiac dysfunction. Free Radic Biol Med 45 (2008), 855–865.
38. Adlam, VJ, Harrison, JC, Porteous, CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19 (2005), 1088–1095.
39. Hamid, SA, Totzeck, M, Drexhage, C, et al. Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium. Basic Res Cardiol 105 (2010), 257–266.
40. Kannan, MS, Prakash, YS, Johnson, DE, Sieck, GC, Nitric oxide inhibits calcium release from sarcoplasmic reticulum of porcine tracheal smooth muscle cells. Am J Physiol 272 (1997), L1–L7.
41. Kanai, A, Epperly, M, Pearce, L, et al. Differing roles of mitochondrial nitric oxide synthase in cardiomyocytes and urothelial cells. Am J Physiol Heart Circ Physiol 286 (2004), H13–H21.
42. Zhang, DM, Chai, Y, Erickson, JR, Brown, JH, Bers, DM, Lin, YF, Intracellular signalling mechanism responsible for modulation of sarcolemmal ATP-sensitive potassium channels by nitric oxide in ventricular cardiomyocytes. J Physiol 592 (2014), 971–990.
43. Cheng, TH, Shih, NL, Chen, SY, et al. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol 68 (2005), 1183–1192.
44. Shinmura, K, Xuan, YT, Tang, XL, et al. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90 (2002), 602–608.
45. Rubbo, H, Radi, R, Trujillo, M, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269 (1994), 26066–26075.
46. Kanno, S, Lee, PC, Zhang, Y, et al. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 101 (2000), 2742–2748.
47. Brunner, F, Maier, R, Andrew, P, Wolkart, G, Zechner, R, Mayer, B, Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 57 (2003), 55–62.
48. Engel, H, Friedrich, S, Schleich, C, et al. Enhancing nitric oxide bioavailability via exogen nitric oxide synthase and L-arginine attenuates ischemia-reperfusion-induced microcirculatory alterations. Ann Plast Surg 00 (2014), 1–5.
49. Rastaldo, R, Cappello, S, Folino, A, et al. Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts. J Physiol Pharmacol 61 (2010), 21–27.
50. Gao, S, Yang, Z, Shi, R, et al. Diabetes blocks the cardioprotective effects of sevoflurane postconditioning by impairing Nrf2/Brg1/HO-1 signaling. Eur J Pharmacol 779 (2016), 111–121.
51. Ray, S, Kassan, A, Busija, AR, Rangamani, P, Patel, HH, The plasma membrane as a capacitor for energy and metabolism. Am J Physiol Cell Physiol 310 (2016), C181–C192.
52. Zhao, J, Wang, F, Zhang, Y, et al. Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition. Circulation 128 (2013), S121–S129.
53. Hu, G, Schwartz, DE, Shajahan, AN, et al. Isoflurane, but not sevoflurane, increases transendothelial albumin permeability in the isolated rat lung: role for enhanced phosphorylation of caveolin-1. Anesthesiology 104 (2006), 777–785.
54. Xie, H, Liu, Q, Qiao, S, Jiang, X, Wang, C, Delayed cardioprotection by sevoflurane preconditioning: a novel mechanism via inhibiting Beclin 1-mediated autophagic cell death in cardiac myocytes exposed to hypoxia/reoxygenation injury. Int J Clin Exp Pathol 8 (2015), 217–226.
55. Murry, CE, Jennings, RB, Reimer, KA, Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986), 1124–1136.
56. Yellon, DM, Alkhulaifi, AM, Pugsley, WB, Preconditioning the human myocardium. Lancet 342 (1993), 276–277.
57. Bolli, R, Li, QH, Tang, XL, et al. The late phase of preconditioning and its natural clinical application–gene therapy. Heart Fail Rev 12 (2007), 189–199.
58. Marber, MS, Latchman, DS, Walker, JM, Yellon, DM, Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88 (1993), 1264–1272.
59. Kuzuya, T, Hoshida, S, Yamashita, N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72 (1993), 1293–1299.
60. Yellon, DM, Downey, JM, Spotlight on preconditioning. Cardiovasc Res 55 (2002), 425–428.
61. Liu, GS, Thornton, J, Van Winkle, DM, Stanley, AW, Olsson, RA, Downey, JM, Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84 (1991), 350–356.
62. Wall, TM, Sheehy, R, Hartman, JC, Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270 (1994), 681–689.
63. Schultz, JE, Rose, E, Yao, Z, Gross, GJ, Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268 (1995), H2157–H2161.
64. Nishida, M, Maruyama, Y, Tanaka, R, Kontani, K, Nagao, T, Kurose, H, G alpha(i) and G alpha(o) are target proteins of reactive oxygen species. Nature 408 (2000), 492–495.
65. Das, DK, Maulik, N, Sato, M, Ray, PS, Reactive oxygen species function as second messenger during ischemic preconditioning of heart. Mol Cell Biochem 196 (1999), 59–67.
66. Armstrong, S, Downey, JM, Ganote, CE, Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc Res 28 (1994), 72–77.
67. Ytrehus, K, Liu, Y, Downey, JM, Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266 (1994), H1145–H1152.
68. Saurin, AT, Pennington, DJ, Raat, NJ, Latchman, DS, Owen, MJ, Marber, MS, Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts. Cardiovasc Res 55 (2002), 672–680.
69. Inagaki, K, Hahn, HS, Dorn, GW 2nd, Mochly-Rosen, D, Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation 108 (2003), 869–875.
70. Tong, H, Chen, W, Steenbergen, C, Murphy, E, Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87 (2000), 309–315.
71. Ping, P, Takano, H, Zhang, J, et al. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: a signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 84 (1999), 587–604.
72. Wang, Y, Ashraf, M, Role of protein kinase C in mitochondrial KATP channel-mediated protection against Ca2+ overload injury in rat myocardium. Circ Res 84 (1999), 1156–1165.
73. Hu, K, Duan, D, Li, GR, Nattel, S, Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res 78 (1996), 492–498.
74. Sato, T, O'Rourke, B, Marban, E, Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C. Circ Res 83 (1998), 110–114.
75. Maulik, N, Watanabe, M, Zu, YL, et al. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. FEBS Lett 396 (1996), 233–237.
76. Hausenloy, DJ, Yellon, DM, Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70 (2006), 240–253.
77. Holmuhamedov, EL, Wang, L, Terzic, A, ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria. J Physiol 519:Pt 2 (1999), 347–360.
78. Cohen, MV, Baines, CP, Downey, JM, Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 62 (2000), 79–109.
79. Oldenburg, O, Cohen, MV, Downey, JM, Mitochondrial K(ATP) channels in preconditioning. J Mol Cell Cardiol 35 (2003), 569–575.
80. Garcia-Dorado, D, Rodriguez-Sinovas, A, Ruiz-Meana, M, Inserte, J, Agullo, L, Cabestrero, A, The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res 70 (2006), 274–285.
81. Yellon, DM, Downey, JM, Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003), 1113–1151.
82. Zhao, ZQ, Corvera, JS, Halkos, ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285 (2003), H579–H588.
83. Luo, W, Li, B, Lin, G, Huang, R, Postconditioning in cardiac surgery for tetralogy of Fallot. J Thorac Cardiovasc Surg 133 (2007), 1373–1374.
84. Li, B, Chen, R, Huang, R, Luo, W, Clinical benefit of cardiac ischemic postconditioning in corrections of tetralogy of Fallot. Interact Cardiovasc Thorac Surg 8 (2009), 17–21.
85. Luo, W, Li, B, Chen, R, Huang, R, Lin, G, Effect of ischemic postconditioning in adult valve replacement. Eur J Cardiothorac Surg 33 (2008), 203–208.
86. Fan, Q, Yang, XC, Liu, Y, et al. Postconditioning attenuates myocardial injury by reducing nitro-oxidative stress in vivo in rats and in humans. Clin Sci 120 (2011), 251–261.
87. Hausenloy, DJ, Tsang, A, Yellon, DM, The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15 (2005), 69–75.
88. Skyschally, A, van Caster, P, Boengler, K, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104 (2009), 15–18.
89. Tsang, A, Hausenloy, DJ, Mocanu, MM, Yellon, DM, Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95 (2004), 230–232.
90. Yang, XM, Proctor, JB, Cui, L, Krieg, T, Downey, JM, Cohen, MV, Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44 (2004), 1103–1110.
91. Hausenloy, DJ, Lecour, S, Yellon, DM, Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 14 (2011), 893–907.
92. Darling, CE, Jiang, R, Maynard, M, Whittaker, P, Vinten-Johansen, J, Przyklenk, K, Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 289 (2005), H1618–H1626.
93. Schwartz, LM, Lagranha, CJ, Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 290 (2006), H1011–H1018.
94. Lacerda, L, Somers, S, Opie, LH, Lecour, S, Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84 (2009), 201–208.
95. Lecour, S, Suleman, N, Deuchar, GA, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112 (2005), 3911–3918.
96. Levy, DE, Lee, CK, What does Stat3 do?. J Clin Invest 109 (2002), 1143–1148.
97. Myers, MG Jr, Cell biology. Moonlighting in mitochondria. Science 323 (2009), 723–724.
98. Wegrzyn, J, Potla, R, Chwae, YJ, et al. Function of mitochondrial Stat3 in cellular respiration. Science 323 (2009), 793–797.
99. Heusch, G, Musiolik, J, Gedik, N, Skyschally, A, Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 109 (2011), 1302–1308.
100. Boengler, K, Buechert, A, Heinen, Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102 (2008), 131–135.
101. Suleman, N, Somers, S, Smith, R, Opie, LH, Lecour, SC, Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 79 (2008), 127–133.
102. Boengler, K, Hilfiker-Kleiner, D, Heusch, G, Schulz, R, Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105 (2010), 771–785.
103. Schmidt, MR, Smerup, M, Konstantinov, IE, et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 292 (2007), H1883–H1890.
104. Kerendi, F, Kin, H, Halkos, ME, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 100 (2005), 404–412.
105. Birnbaum, Y, Hale, SL, Kloner, RA, Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 96 (1997), 1641–1646.
106. Cheung, MM, Kharbanda, RK, Konstantinov, IE, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 47 (2006), 2277–2282.
107. Rahman, IA, Mascaro, JG, Steeds, RP, et al. Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment?. Circulation 122 (2010), S53–S59.
108. Karuppasamy, P, Chaubey, S, Dew, T, et al. Remote intermittent ischemia before coronary artery bypass graft surgery: a strategy to reduce injury and inflammation?. Basic Res Cardiol 106 (2011), 511–519.
109. Kleinbongard, P, Neuhauser, M, Thielmann, M, et al. Confounders of cardioprotection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting. Cardiology 133 (2016), 128–133.
110. Thielmann, M, Kottenberg, E, Kleinbongard, P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382 (2013), 597–604.
111. Meybohm, P, Bein, B, Brosteanu, O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373 (2015), 1397–1407.
112. Hausenloy, DJ, Candilio, L, Evans, R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373 (2015), 1408–1417.
113. Jovic, M, Stancic, A, Nenadic, D, et al. Mitochondrial molecular basis of sevoflurane and propofol cardioprotection in patients undergoing aortic valve replacement with cardiopulmonary bypass. Cell Physiol Biochem 29 (2012), 131–142.
114. Botker, HE, Kharbanda, R, Schmidt, MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375 (2010), 727–734.
115. Yamaguchi, T, Izumi, Y, Nakamura, Y, et al. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol 178 (2015), 239–246.
116. Zhu, XH, Yuan, HJ, Wu, YN, et al. Non-invasive limb ischemic pre-conditioning reduces oxidative stress and attenuates myocardium ischemia-reperfusion injury in diabetic rats. Free Radic Res 45 (2011), 201–210.
117. Wang, C, Li, H, Xia, Z, Irwin, MG, Repeated non-invasive remote ischemic preconditioning confers cardioprotection in diabetic rats. Expe Biol: FASEB J, LB559, 2014.
118. Heusch, G, Botker, HE, Przyklenk, K, Redington, A, Yellon, D, Remote ischemic conditioning. J Am Coll Cardiol 65 (2015), 177–195.
119. Tanaka, K, Weihrauch, D, Kehl, F, et al. Mechanism of preconditioning by isoflurane in rabbits: a direct role for reactive oxygen species. Anesthesiology 97 (2002), 1485–1490.
120. Xia, Z, Godin, DV, Ansley, DM, Propofol enhances ischemic tolerance of middle-aged rat hearts: effects on 15-F(2t)-isoprostane formation and tissue antioxidant capacity. Cardiovasc Res 59 (2003), 113–121.
121. Zhang, Y, Irwin, MG, Lu, Y, et al. Intracerebroventricular administration of morphine confers remote cardioprotection–role of opioid receptors and calmodulin. Eur J Pharmacol 656 (2011), 74–80.
122. Wong, GT, Huang, Z, Ji, S, Irwin, MG, Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 24 (2010), 790–796.
123. Schultz, JE, Hsu, AK, Gross, GJ, Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 78 (1996), 1100–1104.
124. Murphy, GS, Szokol, JW, Marymont, JH, Avram, MJ, Vender, JS, Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 20 (2006), 493–502.
125. Qiao, S, Mao, X, Wang, Y, et al. Remifentanil preconditioning reduces postischemic myocardial infarction and improves left ventricular performance via activation of the Janus activated kinase-2/signal transducers and activators of transcription-3 signal pathway and subsequent inhibition of glycogen synthase kinase-3beta in rats. Crit Care Med 44 (2016), e131–e145.
126. Lam, CF, Liu, YC, Tseng, FL, et al. High-dose morphine impairs vascular endothelial function by increased production of superoxide anions. Anesthesiology 106 (2007), 532–537.
127. Mei, B, Wang, T, Wang, Y, Xia, Z, Irwin, MG, Wong, GT, High dose remifentanil increases myocardial oxidative stress and compromises remifentanil infarct-sparing effects in rats. Eur J Pharmacol 718 (2013), 484–492.
128. Zhang, J, Wang, C, Yu, S, et al. Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signaling. Scientific Reports, 4, 2014, 7317.
129. Shravah, J, Wang, B, Pavlovic, M, et al. Propofol mediates signal transducer and activator of transcription 3 activation and crosstalk with phosphoinositide 3-kinase/AKT. JAKSTAT, 3, 2014, e29554.
130. Li, S, Xu, J, Yao, W, et al. Sevoflurane pretreatment attenuates TNF-alpha-induced human endothelial cell dysfunction through activating eNOS/NO pathway. Biochem Biophys Res Commun 460 (2015), 879–886.
131. Lorsomradee, S, Cromheecke, S, Lorsomradee, S, De Hert, SG, Effects of sevoflurane on biomechanical markers of hepatic and renal dysfunction after coronary artery surgery. J Cardiothorac Vasc Anesth 20 (2006), 684–690.
132. Laviolle, B, Basquin, C, Aguillon, D, et al. Effect of an anesthesia with propofol compared with desflurane on free radical production and liver function after partial hepatectomy. Fundam Clin Pharmacol 26 (2012), 735–742.
133. Beck-Schimmer, B, Bonvini, JM, Schadde, E, et al. Conditioning with sevoflurane in liver transplantation: results of a multicenter randomized controlled trial. Transplantation 99 (2015), 1606–1612.
134. Ozgul, U, Ucar, M, Erdogan, MA, et al. Effects of isoflurane and propofol on hepatic and renal functions and coagulation profile after right hepatectomy in living donors. Transplant Proc 45 (2013), 966–970.
135. Yang, LQ, Tao, KM, Liu, YT, et al. Remifentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats via inducible nitric oxide synthase expression. Anesthesiology 114 (2011), 1036–1047.
136. Cho, SS, Rudloff, I, Berger, PJ, et al. Remifentanil ameliorates intestinal ischemia-reperfusion injury. BMC Gastroenterol, 13, 2013, 69.
137. Belhomme, D, Peynet, J, Louzy, M, Launay, JM, Kitakaze, M, Menasche, P, Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 100 (1999), II340–II344.
138. Huang, Z, Zhong, X, Irwin, MG, et al. Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients. Clin Sci 121 (2011), 57–69.
139. Wang, J, Zheng, H, Chen, CL, Lu, W, Zhang, YQ, Sevoflurane at 1 MAC provides optimal myocardial protection during off-pump CABG. Scand Cardiovasc J 47 (2013), 175–184.
140. Xia, Z, Huang, Z, Ansley, DM, Large-dose propofol during cardiopulmonary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: a comparison with isoflurane. Anesth Analg 103 (2006), 527–532.
141. Tritapepe, L, Landoni, G, Guarracino, F, et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 24 (2007), 323–331.
142. Wang, X, Jarvinen, O, Kuukasjarvi, P, et al. Isoflurane produces only minor preconditioning in coronary artery bypass grafting. Scand Cardiovasc J 38 (2004), 287–292.
143. Soro, M, Gallego, L, Silva, V, et al. Cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery: a double-blind randomised study. Eur J Anaesthesiol 29 (2012), 561–569.
144. Straarup, TS, Hausenloy, DJ, Rolighed Larsen, JK, Cardiac troponins and volatile anaesthetics in coronary artery bypass graft surgery: A systematic review, meta-analysis and trial sequential analysis. Eur J Anaesthesiol 33 (2016), 396–407.
145. De Hert, S, Cardiac troponins and volatile anaesthetics in on-pump coronary surgery: How much longer do we need to state the obvious?. Eur J Anaesthesiol 33 (2016), 393–395.
146. Jakobsen, CJ, Berg, H, Hindsholm, KB, Faddy, N, Sloth, E, The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 21 (2007), 664–671.
147. Zaugg, M, Is protection by inhalation agents volatile? Controversies in cardioprotection. Br J Anaesth 99 (2007), 603–606.
148. Zaugg, M, Lucchinetti, E, Behmanesh, S, Clanachan, AS, Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications. Curr Pharm Des 20 (2014), 5706–5726.
149. Balakumar, P, Sharma, NK, Healing the diabetic heart: does myocardial preconditioning work?. Cell Signal 24 (2012), 53–59.
150. Katayama, T, Nakashima, H, Takagi, C, et al. Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty. Int Heart J 46 (2005), 607–618.
151. Alegria, JR, Miller, TD, Gibbons, RJ, Yi, QL, Yusuf, S, Collaborative Organization of RheothRx Evaluation Trial I. Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 154 (2007), 743–750.
152. Marso, SP, Miller, T, Rutherford, BD, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 100 (2007), 206–210.
153. Zuanetti, G, Latini, R, Maggioni, AP, Santoro, L, Franzosi, MG, Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 22 (1993), 1788–1794.
154. Chyun, D, Obata, J, Kling, J, Tocchi, C, In-hospital mortality after acute myocardial infarction in patients with diabetes mellitus. Am J Crit Care 9 (2000), 168–179.
155. Giordano, FJ, Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115 (2005), 500–508.
156. Webster, KA, Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species. Future Cardiol 8 (2012), 863–884.
157. Cha, MJ, Jang, JK, Ham, O, et al. MicroRNA-145 suppresses ROS-induced Ca2+ overload of cardiomyocytes by targeting CaMKIIdelta. Biochem Biophys Res Commun 435 (2013), 720–726.
158. Lin, J, Wang, T, Li, Y, et al. N-acetylcysteine restores sevoflurane postconditioning cardioprotection against myocardial ischemia-reperfusion injury in diabetic rats. J Diabetes Res, 2016, 2016, 9213034.
159. Whittington, HJ, Harding, I, Stephenson, CI, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 99 (2013), 694–704.
160. Gross, ER, Hsu, AK, Gross, GJ, Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56 (2007), 127–136.
161. Zhang, FJ, Ma, LL, Wang, WN, et al. Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling. Shock 37 (2012), 485–491.
162. Ma, LL, Zhang, FJ, Qian, LB, et al. Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of the MG53/RISK/GSK3beta signaling. Int J Cardiol 168 (2013), 3671–3678.
163. Andersen, A, Povlsen, JA, Botker, HE, Nielsen-Kudsk, JE, Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-conditioning. Eur J Heart Fail 15 (2013), 1208–1214.
164. Lee, JH, Park, YH, Byon, HJ, Kim, HS, Kim, CS, Kim, JT, Effect of remote ischaemic preconditioning on ischaemic-reperfusion injury in pulmonary hypertensive infants receiving ventricular septal defect repair. Br J Anaesth 108 (2012), 223–228.
165. Ferdinandy, P, Hausenloy, DJ, Heusch, G, Baxter, GF, Schulz, R, Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66 (2014), 1142–1174.
166. Lou, PH, Zhang, L, Lucchinetti, E, et al. Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury. Cardiovasc Res 97 (2013), 251–261.
167. Loubani, M, Fowler, A, Standen, NB, Galinanes, M, The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 515 (2005), 142–149.
168. Sloth, AD, Schmidt, MR, Munk, K, et al. Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial. Br Med J Open, 5, 2015, e006923.
169. Liu, X, Liu, X, Wang, R, et al. Circulating microRNAs indicate cardioprotection by sevoflurane inhalation in patients undergoing off-pump coronary artery bypass surgery. Exp Ther Med 11 (2016), 2270–2276.
170. Bulow, NM, Colpo, E, Pereira, RP, et al. Dexmedetomidine decreases the inflammatory response to myocardial surgery under mini-cardiopulmonary bypass. Braz J Med Biol Res, 49, 2016, e4646.
171. Rogers, CA, Bryan, AJ, Nash, R, et al. Propofol cardioplegia: a single-center, placebo-controlled, randomized controlled trial. J Thorac Cardiovasc Surg 150 (2015), 1610–1619 e13.
172. Jia, L, Dong, R, Zhang, F, et al. Propofol provides more effective protection for circulating lymphocytes than sevoflurane in patients undergoing off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 29 (2015), 1172–1179.
173. Sirvinskas, E, Kinderyte, A, Trumbeckaite, S, et al. Effects of sevoflurane vs. propofol on mitochondrial functional activity after ischemia-reperfusion injury and the influence on clinical parameters in patients undergoing CABG surgery with cardiopulmonary bypass. Perfusion 30 (2015), 590–595.
174. Jerath, A, Beattie, SW, Chandy, T, et al. Volatile-based short-term sedation in cardiac surgical patients: a prospective randomized controlled trial. Crit Care Med 43 (2015), 1062–1069.
175. Landoni, G, Guarracino, F, Cariello, C, et al. Volatile compared with total intravenous anaesthesia in patients undergoing high-risk cardiac surgery: a randomized multicentre study. Br J Anaesth 113 (2014), 955–963.
176. Kim, HJ, Kim, WH, Kim, G, et al. A comparison among infusion of lidocaine and dexmedetomidine alone and in combination in subjects undergoing coronary artery bypass graft: a randomized trial. Contemp Clin Trials 39 (2014), 303–309.
177. Yilmaz, M, Aydin, U, Arslan, ZI, et al. The effect of lidocaine and amiodarone on prevention of ventricular fibrillation in patients undergoing coronary artery bypass grafting. Heart Surg Forum 17 (2014), E245–E249.
178. Mrozinski, P, Lango, R, Biedrzycka, A, Kowalik, MM, Pawlaczyk, R, Rogowski, J, Comparison of haemodynamics and myocardial injury markers under desflurane vs. propofol anaesthesia for off-pump coronary surgery. A prospective randomised trial. Anaesthesiol Intensive Ther 46 (2014), 4–13.
179. Guerrero Orriach, JL, Galan Ortega, M, Ramirez Aliaga, M, Iglesias, P, Rubio Navarro, M, Cruz Manas, J, Prolonged sevoflurane administration in the off-pump coronary artery bypass graft surgery: beneficial effects. J Crit Care, 28, 2013 879 e13-8.
180. Suryaprakash, S, Chakravarthy, M, Muniraju, G, et al. Myocardial protection during off pump coronary artery bypass surgery: a comparison of inhalational anesthesia with sevoflurane or desflurane and total intravenous anesthesia. Ann Card Anaesth 16 (2013), 4–8.
181. Bassuoni, AS, Amr, YM, Cardioprotective effect of sevoflurane in patients with coronary artery disease undergoing vascular surgery. Saudi J Anaesth 6 (2012), 125–130.
182. Imantalab, V, Seddighi Nejad, A, Mir Mansouri, A, et al. A comparative study of cardioprotective effect of three anesthetic agents by measuring serum level of troponin-T after coronary artery bypass grafting. Int Cardiovasc Res J 6 (2012), 70–74.
183. Riha, H, Kotulak, T, Brezina, A, et al. Comparison of the effects of ketamine-dexmedetomidine and sevoflurane-sufentanil anesthesia on cardiac biomarkers after cardiac surgery: an observational study. Physiol Res 61 (2012), 63–72.
184. Ceyhan, D, Tanriverdi, B, Bilir, A, Comparison of the effects of sevoflurane and isoflurane on myocardial protection in coronary bypass surgery. Anadolu Kardiyol Derg 11 (2011), 257–262.
185. Lee, EH, Lee, HM, Chung, CH, et al. Impact of intravenous lidocaine on myocardial injury after off-pump coronary artery surgery. Br J Anaesth 106 (2011), 487–493.
186. Tempe, DK, Dutta, D, Garg, M, Minhas, H, Tomar, A, Virmani, S, Myocardial protection with isoflurane during off-pump coronary artery bypass grafting: a randomized trial. J Cardiothorac Vasc Anesth 25 (2011), 59–65.
187. Amr, YM, Yassin, IM, Cardiac protection during on-pump coronary artery bypass grafting: ischemic versus isoflurane preconditioning. Semin Cardiothorac Vasc Anesth 14 (2010), 205–211.
188. Frassdorf, J, Borowski, A, Ebel, D, et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. J Thorac Cardiovasc Surg 137 (2009), 1436–1442 42 e1-2.
189. Cho, JE, Shim, JK, Choi, YS, Kim, DH, Hong, SW, Kwak, YL, Effect of low-dose ketamine on inflammatory response in off-pump coronary artery bypass graft surgery. Br J Anaesth 102 (2009), 23–28.
190. Winterhalter, M, Brandl, K, Rahe-Meyer, N, et al. Endocrine stress response and inflammatory activation during CABG surgery. A randomized trial comparing remifentanil infusion to intermittent fentanyl. Eur J Anaesthesiol 25 (2008), 326–335.
191. Piriou, V, Mantz, J, Goldfarb, G, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth 99 (2007), 624–631.
192. Meco, M, Cirri, S, Gallazzi, C, Magnani, G, Cosseta, D, Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo-controlled study. Eur J Cardiothorac Surg 32 (2007), 319–325.
193. Murphy, GS, Szokol, JW, Marymont, JH, Avram, MJ, Vender, JS, The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery. Anesth Analg 104 (2007), 1334–1342 table of contents.
194. Corcoran, TB, Engel, A, Sakamoto, H, O'Shea, A, O'Callaghan-Enright, S, Shorten, GD, The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth 97 (2006), 825–831.
195. Lee, MC, Chen, CH, Kuo, MC, Kang, PL, Lo, A, Liu, K, Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. Eur J Anaesthesiol 23 (2006), 841–847.
196. Cromheecke, S, Pepermans, V, Hendrickx, E, et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 103 (2006), 289–296 table of contents.
197. Garcia, C, Julier, K, Bestmann, L, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 94 (2005), 159–165.
198. Conzen, PF, Fischer, S, Detter, C, Peter, K, Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 99 (2003), 826–833.
199. Julier, K, da Silva, R, Garcia, C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 98 (2003), 1315–1327.